Clinical trial · Observational
Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL
Predictive Value of CRP, Albumin, CAR, and mGPS in DLBCL: A Prospective Cohort Study on Treatment Outcomes and Toxicity
NCT07057765CI-TRIAL-00091961recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This observational study evaluates the predictive value of systemic inflammatory markers-CRP, albumin, CRP-to-albumin ratio (CAR), and modified Glasgow Prognostic Score (mGPS)-in patients with diffuse large B-cell lymphoma (DLBCL) receiving R-CHOP chemotherapy. The study examines associations with treatment response, toxicity, and clinical characteristics.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| DLBCL - Diffuse Large B Cell Lymphoma | Interdigitating Dendritic Cell Sarcoma | PROBABILISTIC | 0.70 |
| Markers of Inflammation | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Observational Assessment of Standard R-CHOP Treatment | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with DLBCL Treated with R-CHOP (Observational Group)
- description
- Patients diagnosed with diffuse large B-cell lymphoma (DLBCL) who are receiving R-CHOP chemotherapy as part of standard clinical care. This observational study aims to evaluate the predictive value of baseline inflammatory markers (CRP, albumin, CAR, and mGPS) on treatment response and toxicity. No study-specific interventions are administered.
- interventionNames
- Drug: Observational Assessment of Standard R-CHOP Treatment
Primary outcomes (2)
- measure
- Objective Response Rate (ORR) Following 3 Cycles of R-CHOP Based on Baseline Inflammatory Markers
- timeFrame
- Baseline (Day 1 of Cycle 1) and Day 63 (End of Cycle 3; each cycle is 21 days)
- description
- Proportion ( %) of patients achieving an objective response (complete or partial) according to the Lugano classification after three cycles of R-CHOP chemotherapy. Patients will be stratified by baseline inflammatory markers: * C-reactive protein (CRP, mg/L, measured by immunoturbidimetric assay) * Serum albumin (g/dL, measured by colorimetric assay) * CRP/Albumin ratio (CAR, calculated as CRP divided by albumin) * Modified Glasgow Prognostic Score (mGPS, range 0-2) Response will be assessed using PET/CT imaging.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years and ≤ 65 years * Pathologically confirmed, treatment-naïve diffuse large B-cell lymphoma (DLBCL) * Any stage of disease (nodal or extra-nodal), with or without B symptoms * Scheduled to receive standard systemic treatment (R-CHOP) * ECOG performance status 0-2 * Baseline normal: * Complete blood count (CBC) * Hepatitis viral markers * Liver and renal function tests * Urine analysis * Echocardiogram * Additional investigations to exclude current infection if clinically indicated Exclusion Criteria: * History of other concurrent or previous malignancies * Relapsed or refractory DLBCL * Uncontrolled comorbid conditions that may interfere with study participation, including: * Diabetes mellitus * Autoimmune diseases * Active infections * Chronic inflammatory diseases * Cardiac dysfunction * Liver cell failure * Pregnant females
References
Publications (0)
Data not yet available
No reference posted for this study.